Hydroxychloroquine use in the COVID-19 patient.
Journal
Cleveland Clinic journal of medicine
ISSN: 1939-2869
Titre abrégé: Cleve Clin J Med
Pays: United States
ID NLM: 8703441
Informations de publication
Date de publication:
02 Sep 2020
02 Sep 2020
Historique:
pubmed:
7
5
2020
medline:
7
5
2020
entrez:
7
5
2020
Statut:
aheadofprint
Résumé
Hydroxychloroquine (HCQ) has multiple potential antiviral mechanisms of action that differ according to the pathogen studied (eg, Chikungunya, Dengue virus, human immunodeficiency virus, poliovirus, Zika virus). Data on HCQ for treatment of COVID-19 are rapidly evolving. To date, there is no evidence from randomized controlled trials that HCQ, or any single therapy, improves outcomes in patients infected with COVID-19. There are also no clinical trial data supporting prophylactic HCQ therapy in COVID-19. Use of HCQ in patients with COVID-19 is being investigated for prophylaxis, postexposure prophylaxis, and treatment.
Identifiants
pubmed: 32371558
pii: ccjm.87a.ccc011
doi: 10.3949/ccjm.87a.ccc011
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.